| Name | Title | Contact Details |
|---|---|---|
Dimitris Agrafiotis |
Chief Digital Officer | Profile |
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Enzymotec develops and manufactures nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies. Since its establishment in 1998, the company has enjoyed accelerated growth, generating impressive sales worldwide, by launching a diverse portfolio of innovative products. Our two business segments leverage our lipid-related expertise: Nutrition and Pharma. Enzymotec's diverse range of products span the entire human life-cycle - from infancy to old age, providing key ingredients for use in infant formula and nutritional supplements, as well as branded medical foods. Enzymotec's multi-disciplinary team, including scientists, engineers and business development professionals, have an outstanding track-record in turning advanced lipid science into commercially attractive, nutritional solutions, constantly enriching our unique cluster of technology and expertise.
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx`s expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg`s lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.
Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer.
Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.